| Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy AJ Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, J Van Lunzen, ... Jama 316 (2), 171-181, 2016 | 1698 | 2016 |
| Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies A Trickey, MT May, JJ Vehreschild, N Obel, MJ Gill, HM Crane, ... The lancet HIV 4 (8), e349-e356, 2017 | 1096 | 2017 |
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ... European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010 | 441 | 2010 |
| Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis A Diez‐Ruiz, GP Tilz, R Zangerle, G Baier‐Bitterlich, H Wachter, D Fuchs European journal of haematology 54 (1), 1-8, 1995 | 391 | 1995 |
| Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study … A Mocroft, JD Lundgren, ML Sabin, AA Monforte, N Brockmeyer, ... PLoS medicine 10 (9), e1001510, 2013 | 388 | 2013 |
| Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority … JM Molina, K Squires, PE Sax, P Cahn, J Lombaard, E DeJesus, MT Lai, ... The lancet HIV 5 (5), e211-e220, 2018 | 209 | 2018 |
| Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study) AK Sullivan, D Raben, J Reekie, M Rayment, A Mocroft, S Esser, A Leon, ... PloS one 8 (1), e52845, 2013 | 205 | 2013 |
| Long-term mortality in HIV-positive individuals virally suppressed for> 3 years with incomplete CD4 recovery FN Engsig, R Zangerle, O Katsarou, F Dabis, P Reiss, J Gill, K Porter, ... Clinical infectious diseases 58 (9), 1312-1321, 2014 | 195 | 2014 |
| Do gender differences in CD4 cell counts matter? M Prins, JR Robertson, RP Brettle, IH Aguado, B Broers, F Boufassa, ... Aids 13 (17), 2361-2364, 1999 | 177 | 1999 |
| Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis L Van Asten, I Verhaest, S Lamzira, I Hernandez-Aguado, R Zangerle, ... The Journal of infectious diseases 189 (2), 292-302, 2004 | 173 | 2004 |
| Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS … A Babiker, S Darby, D De Angelis, D Kwart, K Porter, V Beral, ... Lancet 355 (9210), 2000 | 148 | 2000 |
| Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 … A Cozzi-Lepri, M Noguera-Julian, F Di Giallonardo, R Schuurman, ... Journal of antimicrobial chemotherapy 70 (3), 930-940, 2015 | 142 | 2015 |
| Association between immune activation, changes of iron metabolism and anaemia in patients with HIV infection D Fuchs, R Zangerle, E Artner‐Dworzak, G Weiss, P Fritsch, GP Tilz, ... European journal of haematology 50 (2), 90-94, 1993 | 136 | 1993 |
| Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation R Zangerle, M Sarcletti, H Gallati, G Reibnegger, H Wachter, D Fuchs JAIDS Journal of Acquired Immune Deficiency Syndromes 7 (11), 1149-1156, 1994 | 135 | 1994 |
| Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts G Touloumi, N Pantazis, D Pillay, D Paraskevis, ML Chaix, HC Bucher, ... Clinical infectious diseases 56 (6), 888-897, 2013 | 134 | 2013 |
| The incidence of AIDS-defining illnesses at a current CD4 count≥ 200 cells/µL in the post–combination antiretroviral therapy era A Mocroft, HJ Furrer, JM Miro, P Reiss, C Mussini, O Kirk, S Abgrall, ... Clinical infectious diseases 57 (7), 1038-1047, 2013 | 133 | 2013 |
| Cause-specific mortality in HIV-positive patients who survived ten years after starting antiretroviral therapy A Trickey, MT May, J Vehreschild, N Obel, MJ Gill, H Crane, C Boesecke, ... PloS one 11 (8), e0160460, 2016 | 132 | 2016 |
| Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection R Zangerle, B Widner, G Quirchmair, G Neurauter, M Sarcletti, D Fuchs Clinical Immunology 104 (3), 242-247, 2002 | 115 | 2002 |
| High risk of developing toxoplasmic encephalitis in AIDS patients seropositive to Toxoplasma gondii R Zangerle, F Allerberger, P Pohl, P Fritsch, MP Dierich Medical microbiology and immunology 180 (2), 59-66, 1991 | 101 | 1991 |
| Non-AIDS defining cancers in the D: A: D Study-time trends and predictors of survival: a cohort study SW Worm, M Bower, P Reiss, F Bonnet, M Law, G Fätkenheuer, ... BMC infectious diseases 13, 1-15, 2013 | 100 | 2013 |
Ildefonso Hernández-Aguado OR Ildef...Professor of Public Health, University Miguel Hernández, SpainVerified email at umh.es
